1 |
dpavlin |
1.1 |
<div align="Center"><b>PLIVA major contributor at ICMAS-KO 6<br> |
2 |
|
|
</b></div> |
3 |
|
|
<br> |
4 |
|
|
<i>Bologna, 23-26 January 2002</i><br> |
5 |
|
|
<br> |
6 |
|
|
ICMAS-KO is the International Conference on the Macrolides, Azalides, Streptogramins, |
7 |
|
|
Ketolides & Oxazolidinones. It is the biggest international scientific |
8 |
|
|
event concerning macrolides and similar compounds. The purpose of the ICMAS |
9 |
|
|
conferences is to address current issues and future trends in the development |
10 |
|
|
and uses of these agents. The conference has been held every 2 years since |
11 |
|
|
1992. <br> |
12 |
|
|
PLIVA has been a sponsor of this event since 1996. In year 2002, PLIVA was |
13 |
|
|
one of the major contributors of the conference along with Pfizer Inc., Abbott |
14 |
|
|
Laboratories and Aventis.<br> |
15 |
|
|
<br> |
16 |
|
|
<div align="Center"><img src="/comm/stand-fJPG.jpg" alt="" width="300" height="225"> |
17 |
|
|
<br> |
18 |
|
|
<br> |
19 |
|
|
PLIVA exibition area at ICMASKO 6<br> |
20 |
|
|
<br> |
21 |
|
|
</div> |
22 |
|
|
<br> |
23 |
|
|
ICMAS-KO 6 was held in Bologna, Italy from January 23-26, 2002. It gathered |
24 |
|
|
about 800 delegates. The scientific program was organised in parallel sessions |
25 |
|
|
with the following content: |
26 |
|
|
<ul> |
27 |
|
|
<li>Plenary session</li> |
28 |
|
|
<ul> |
29 |
|
|
<li>New Microbial Targets for the MASKO Compounds</li> |
30 |
|
|
</ul> |
31 |
|
|
<li>5 workshop seminars:</li> |
32 |
|
|
<ul> |
33 |
|
|
<li>Evolving patterns of resistance mechanisms and prevalence,</li> |
34 |
|
|
</ul> |
35 |
|
|
<ul> |
36 |
|
|
<li>Issues in pharmacology and metabolism of MASKO compounds,</li> |
37 |
|
|
</ul> |
38 |
|
|
<ul> |
39 |
|
|
<li>In vitro activity of new MASKO compounds,</li> |
40 |
|
|
</ul> |
41 |
|
|
<ul> |
42 |
|
|
<li>Clinical infections: adult and paediatric,</li> |
43 |
|
|
</ul> |
44 |
|
|
<ul> |
45 |
|
|
<li>H.- pylori, other special pathogens and non-antibacterial effects |
46 |
|
|
of MASKO compounds)</li> |
47 |
|
|
</ul> |
48 |
|
|
<li>2 laboratory workshops</li> |
49 |
|
|
<ul> |
50 |
|
|
<li>Susceptibility testing of challenging microbes including streptococci, |
51 |
|
|
staphylococci, haemophillus and intracellular pathogens</li> |
52 |
|
|
</ul> |
53 |
|
|
<ul> |
54 |
|
|
<li>Specific techniques to detect and characterise resistance mechanisms</li> |
55 |
|
|
</ul> |
56 |
|
|
<li>3 company- sponsored symposia (Pfizer, Abbott and Aventis)</li> |
57 |
|
|
<li>Keynote lecture</li> |
58 |
|
|
<ul> |
59 |
|
|
<li>Countering the emergence of resistance to MASKO agents</li> |
60 |
|
|
</ul> |
61 |
|
|
</ul> |
62 |
|
|
<br> |
63 |
|
|
<br> |
64 |
|
|
A total of 196 posters were presented including 50 posters supported by PLIVA.<br> |
65 |
|
|
<br> |
66 |
|
|
<div align="Center"><img src="/comm/poster-f.JPG" alt="" width="300" height="225"> |
67 |
|
|
<br> |
68 |
|
|
<br> |
69 |
|
|
PLIVA has sponsored 50 poster presentations at ICMASKO 6<br> |
70 |
|
|
<br> |
71 |
|
|
</div> |
72 |
|
|
<br> |
73 |
|
|
The majority of PLIVA sponsored posters were discussed during workshop seminars |
74 |
|
|
particularly those once dealing with possible new indications.<br> |
75 |
|
|
<br> |
76 |
|
|
<div align="Center"><img src="/comm/petricekpredavanja-f.JPG" alt="" width="300" height="225"> |
77 |
|
|
<br> |
78 |
|
|
<br> |
79 |
|
|
The majority of PLIVA sopnsored posters were discussed during workshop seminars |
80 |
|
|
<br> |
81 |
|
|
<br> |
82 |
|
|
</div> |
83 |
|
|
<br> |
84 |
|
|
<i><u>Atherosclerosis</u></i><br> |
85 |
|
|
Croatian Azithromycin in Atherosclerosis Study (CROAATS) was one of two papers |
86 |
|
|
presented in that field. The role of azithromycin in the secondary prevention |
87 |
|
|
of adverse cardiovascular events in C. pneumoniae-positive post-myocardial |
88 |
|
|
infarction patients is still to be defined. Some data from Azithromycin Coronary |
89 |
|
|
Events Study (ACES) were also presented but the study is to be finished |
90 |
|
|
in December 2003 and for the time being the presented results are inconclusive.<br> |
91 |
|
|
<br> |
92 |
|
|
<i><u>H.pylori infections</u></i><br> |
93 |
|
|
Four presented H. pylori studies were considered to be very interesting because |
94 |
|
|
up to know limited data was available about azithromycin therapy in the treatment |
95 |
|
|
of H.pylori infection. According to the presented results azithromycin, as |
96 |
|
|
a part of triple therapy, appears to be of equal clinical and bacteriological |
97 |
|
|
efficacy as triple therapies containing clarithromycin .The advantage of |
98 |
|
|
azithromycin is in simple and short dosage regimen.<br> |
99 |
|
|
<br> |
100 |
|
|
<u><i>Other infections</i></u><br> |
101 |
|
|
The posters dealing with new possible azithromycin indications as acne and |
102 |
|
|
chlamydial conjunctivitis also took part in workshop seminars. Single dose |
103 |
|
|
of azithromycin was as effective as standard regimen of doxycycline twice |
104 |
|
|
daily for 10 days in the treatment of chlamydial conjunctivitis. The preliminary |
105 |
|
|
results of acne study support earlier reports on the safety and efficacy |
106 |
|
|
of azithromycin pulse therapy in acne treatment. The final findings of the |
107 |
|
|
study will be used as a basis for planning a pivotal comparative trial in |
108 |
|
|
acne patients. <br> |
109 |
|
|
The case report of azithromycin in the therapy of actinomycosis was particularly |
110 |
|
|
attractive because of completely new indication area and new dosage regimen |
111 |
|
|
(prolonged azithromycin treatment) as well as gathered safety data.<br> |
112 |
|
|
According to the presented papers azithromycin seems to be effective therapy |
113 |
|
|
in the treatment of cat scratch disease and shows encouraging results in |
114 |
|
|
the treatment of respiratory infections in oncology patients.<br> |
115 |
|
|
<br> |
116 |
|
|
<br> |
117 |
|
|
<b>PLIVA satellite symposium: Sumamed – today and tomorrow<br> |
118 |
|
|
<br> |
119 |
|
|
</b> |
120 |
|
|
<div align="Center"><img src="/comm/sastanaksledja-f.JPG" alt="" width="300" height="225"> |
121 |
|
|
<br> |
122 |
|
|
<br> |
123 |
|
|
Sumamed today and tomorrow <br> |
124 |
|
|
</div> |
125 |
|
|
<br> |
126 |
|
|
<br> |
127 |
|
|
On January 26 all PLIVA sponsored participants were invited to the PLIVA |
128 |
|
|
meeting with following program: |
129 |
|
|
<ol> |
130 |
|
|
<li>PLIVA today & tomorrow (Mr. Gerard Cole)</li> |
131 |
|
|
<li>Mechanisms of macrolide resistance (Viktorija Tomic, MD)</li> |
132 |
|
|
<li>Antimicrobial resistance in Russia (Sergei V. Sidorenko, MD. PhD)</li> |
133 |
|
|
<li>The position of macrolides in the treatment of respiratory tract infections |
134 |
|
|
(Bruno Barsic, MD. PhD)</li> |
135 |
|
|
<li>Azithromycin - Future perspectives (Artur Banaszak, MD)</li> |
136 |
|
|
</ol> |
137 |
|
|
The main issue of the meeting was the problem of the antibacterial resistance |
138 |
|
|
and its impact on clinical practice. As it was mentioned in report of Abbott |
139 |
|
|
symposium the general impression is that obvious contradiction in results |
140 |
|
|
exist. The results from clinical studies from early and late 90`s show that |
141 |
|
|
there is no change in macrolide efficacy in the treatment of RTI in the last |
142 |
|
|
decate despite reported dramatic increase of laboratory resistance. It opens |
143 |
|
|
lot of questions: is resistance rate overestimated, are MIC breakpoints well |
144 |
|
|
established - should they be changed, what about influence on immune |
145 |
|
|
system?<br> |
146 |
|
|
<br> |
147 |
|
|
The final conclusions of the meeting were: |
148 |
|
|
<ul> |
149 |
|
|
<li>Susceptibility testing is performed by different methods – broth microdilution, |
150 |
|
|
agar dilution, disk diffusion, E test, and resistance gene determination |
151 |
|
|
with molecular methods. Published data about resistance are not always based |
152 |
|
|
on standardised methods and does not take in account influence of medium, |
153 |
|
|
incubation atmosphere, length of incubation, inoculum size and colony age |
154 |
|
|
when interpreting results and that is why are sometimes missleading.</li> |
155 |
|
|
<li>In-vitro and. in-vivo conditions are dfferent (immune response |
156 |
|
|
of the host)</li> |
157 |
|
|
<li>Pharmacokinetic/pharmacodynamic parameters of the antimicrobial infuence |
158 |
|
|
the clinical outcome</li> |
159 |
|
|
<li>Factors associated with individual patients should be also taken into |
160 |
|
|
account::</li> |
161 |
|
|
<ul> |
162 |
|
|
<li>outpatient/inpatient, compliance</li> |
163 |
|
|
</ul> |
164 |
|
|
<ul> |
165 |
|
|
<li>age, comorbidity, clinical status</li> |
166 |
|
|
</ul> |
167 |
|
|
<ul> |
168 |
|
|
<li>site of infection, intensity of infection.</li> |
169 |
|
|
</ul> |
170 |
|
|
</ul> |